Targeting kinases for the treatment of inflammatory diseases

Expert Opinion on Drug Discovery

Volumn 5, Issue 9, 2010, Pages 867-881

  Müller, Susanne ^a   Knapp, Stefan ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Emerging targets; IKK; Inflammation; JAK3LCK; MTOR; P38 ; Protein kinases; SYK

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; BMS 582949; CP 690; CYTOKINE; DASATINIB; DEFOROLIMUS; DORAMAPIMOD; EVEROLIMUS; FOSTAMATINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INCB 28024; INCB 28050; INTERLEUKIN 1; INTERLEUKIN 8; JANUS KINASE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PROTEIN KINASE SYK; PROTEIN TYROSINE KINASE INHIBITOR; R 788; RAPAMYCIN; SB 681323; SCIO 469; TEMSIROLIMUS; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VX 509; VX 702; YM 193306;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; GENE MUTATION; GRAFT REJECTION; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE SYSTEM; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INFLAMMATORY DISEASE; INTRACELLULAR SIGNALING; JAK3 DEFICIENCY; KIDNEY CANCER; KIDNEY TRANSPLANTATION; NONHUMAN; ORGAN GROWTH; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; PROTEINASE INHIBITION; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYSTEMIC SCLEROSIS;

EID: 77955945487     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2010.504203     Document Type: Review

References (130)

1. Feldmann M, Williams RO, Paleolog E. What have we learnt from targeted anti-TNF therapy? Ann Rheum Dis 2010;69(Suppl 1):i97-9
2. McCluggage LK, Scholtz JM. Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 2010;44(1):135-144
3. Menter A. The status of biologic therapies in the treatment of moderate to severe psoriasis. Cutis 2009;84(4 Suppl):14-24
4. Williams MD, Omran ML, Gordon GL. Biologic therapy in Crohns disease. Mo Med 2009;106(5):356-360
5. Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009;1(6):583-589
6. Dowling RJ, Topisirovic I, Fonseca BD, Sonenberg N. Dissecting the role of mTOR: lessons from mTOR inhibitors. Biochim Biophys Acta 2010;1804(3):433-439
7. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005;17(6):596-603
8. Dumont FJ, Staruch MJ, Koprak SL, et al. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144(1):251-258
9. Wicker LS, Boltz RC Jr, Matt V, et al. Suppression of B cell activation by cyclosporin A, FK506 and rapamycin. Eur J Immunol 1990;20(10):2277-2283
10. Kay JE, Kromwel L, Doe SE, Denyer M. Inhibition of T and B lymphocyte proliferation by rapamycin. Immunology 1991;72(4):544-549
11. Woltman AM, van der Kooij SW, Coffer PJ, et al. Rapamycin specifically interferes with GM-CSF signaling in human dendritic cells, leading to apoptosis via increased p27KIP1 expression. Blood 2003;101(4):1439-1445
12. Mita M, Sankhala K, Abdel-Karim I, et al. Deforolimus (AP23573) a novel mTOR inhibitor in clinical development. Expert Opin Investig Drugs 2008;17(12):1947-1954
13. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357(25):2562-2575
14. Pallet N, Thervet E, Legendre C, et al. Sirolimus early graft nephrotoxicity: clinical and experimental data. Curr Drug Saf 2006;1(2):179-187
15. Weichhart T, Costantino G, Poglitsch M, et al. The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 2008;29(4):565-577
16. Boulay JL, Oshea JJ, Paul WE. Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 2003;19(2):159-163
17. Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 1994;264(5164):1415-1421
18. Zhou YJ, Chen M, Cusack NA, et al. Unexpected effects of FERM domain mutations on catalytic activity of Jak3: structural implication for Janus kinases. Mol Cell 2001;8(5):959-969
19. Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006;108(1):346-352
20. Haan S, Margue C, Engrand A, et al. Dual role of the Jak1 FERM and kinase domains in cytokine receptor binding and in stimulation-dependent Jak activation. J Immunol 2008;180(2):998-1007
21. Deal watch. dipping into Incytes JAK-pot. Nat Rev Drug Discov 2010;9(2):94
22. Fridman JS, Scherle PA, Collins R, et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2008;184(9):5298-5307
23. Johnston JA, Kawamura M, Kirken RA, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature 1994;370(6485):151-153
24. Leonard WJ, Noguchi M, Russell SM, McBride OW. The molecular basis of X-linked severe combined immunodeficiency: the role of the interleukin-2 receptor gamma chain as a common gamma chain, gamma c. Immunol Rev 1994;138:61-86
25. Asao H, Okuyama C, Kumaki S, et al. Cutting edge: the common gamma-chain is an indispensable subunit of the IL-21 receptor complex. J Immunol 2001;167(1):1-5
26. Sudbeck EA, Liu XP, Narla RK, et al. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents. Clin Cancer Res 1999;5(6):1569-1582
27. Changelian PS, Moshinsky D, Kuhn CF, et al. The specificity of JAK3 kinase inhibitors. Blood 2008;111(4):2155-2157
28. Stepkowski SM, Erwin-Cohen RA, Behbod F, et al. Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. Blood 2002;99(2):680-689
29. Changelian PS, Flanagan ME, Ball DJ, et al. Prevention of organ allograft rejection by a specific Janus kinase 3 inhibitor. Science 2003;302(5646):875- 878
30. DCruz OJ, Uckun FM. Targeting mast cells in endometriosis with janus kinase 3 inhibitor, JANEX-1. Am J Reprod Immunol 2007;58(2):75-97
31. Buckley RH, Schiff RI, Schiff SE, et al. Human severe combined immunodeficiency: genetic, phenotypic, and functional diversity in one hundred eight infants. J Pediatr 1997;130(3):378-387
32. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343(18):1313-1324
33. Notarangelo LD, Giliani S, Mazza C, et al. Of genes and phenotypes: the immunological and molecular spectrum of combined immune deficiency. Defects of the gamma(c)-JAK3 signaling pathway as a model. Immunol Rev 2000;178:39-48
34. Macchi P, Villa A, Giliani S, et al. Mutations of Jak-3 gene in patients with autosomal severe combined immune deficiency (SCID). Nature 1995;377(6544):65-68
35. Russell SM, Tayebi N, Nakajima H, et al. Mutation of Jak3 in a patient with SCID: essential role of Jak3 in lymphoid development. Science 1995;270(5237):797-800
36. OShea JJ, Pesu M, Borie DC, Changelian PS. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat Rev Drug Discov 2004;3(7):555-564
37. OShea JJ, Park H, Pesu M, et al. New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway. Curr Opin Rheumatol 2005;17(3):305-311
38. Boggon TJ, Li Y, Manley PW, Eck MJ. Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 2005;106(3):996-1002
39. Lucet IS, Fantino E, Styles M, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 2006;107(1):176-183
40. Williams NK, Bamert RS, Patel O, et al. Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J Mol Biol 2009;387(1):219-232
41. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26(1):127-132
42. Jiang JK, Ghoreschi K, Deflorian F, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R) -4-methyl-3- (methyl(7H-pyrrolo[2,3-d] pyrimidin-4-yl)amino)piperi din-1-yl)-3- oxopropanenitrile (CP-690,550). J Med Chem 2008;51(24):8012-8018
43. Rousvoal G, Si MS, Lau M, et al. Janus kinase 3 inhibition with CP-690,550 prevents allograft vasculopathy. Transpl Int 2006;19(12):1014-1021
44. Milici AJ, Kudlacz EM, Audoly L, et al. Cartilage preservation by inhibition of Janus kinase 3 in two rodent models of rheumatoid arthritis. Arthritis Res Ther 2008;10(1):R14
45. Borie DC, Changelian PS, Larson MJ, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation 2005;79(7):791-801
46. Opar A. Kinase inhibitors attract attention as oral rheumatoid arthritis drugs. Nat Rev Drug Discov 2010;9(4):257-258
47. Ghoreschi K, Laurence A, OShea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009;228(1):273-287
48. Pesu M, Laurence A, Kishore N, et al. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-142
49. Han J, Lee JD, Bibbs L, Ulevitch RJ. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 1994;265(5173):808-811
50. Freshney NW, Rawlinson L, Guesdon F, et al. Interleukin-1 activates a novel protein kinase cascade that results in the phosphorylation of Hsp27. Cell 1994;78(6):1039-1049
51. Dean JL, Sully G, Clark AR, et al. The involvement of AU-rich element-binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 2004;16(10):1113-1121
52. Clark A, Dean J, Tudor C, Saklatvala J. Post-transcriptional gene regulation by MAP kinases via AU-rich elements. Front Biosci 2009;14:847-871
53. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372(6508):739-746
54. OKeefe SJ, Mudgett JS, Cupo S, et al. Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation. J Biol Chem 2007;282(48):34663-34671
55. Cuenda A, Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007;1773(8):1358-1375
56. Ge B, Gram H, Di Padova F, et al. MAPKK-independent activation of p38alpha mediated by TAB1-dependent autophosphorylation of p38alpha. Science 2002;295(5558):1291-1294
57. Ge B, Xiong X, Jing Q, et al. TAB1beta (transforming growth factor-beta-activated protein kinase 1-binding protein 1beta), a novel splicing variant of TAB1 that interacts with p38alpha but not TAK1. J Biol Chem 2003;278(4):2286-2293
58. Salvador JM, Mittelstadt PR, Belova GI, et al. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway. Nat Immunol 2005;6(4):396-402
59. Salvador JM, Mittelstadt PR, Guszczynski T, et al. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol 2005;6(4):390-395
60. ONeill LA. Targeting signal transduction as a strategy to treat inflammatory diseases. Nat Rev Drug Discov 2006;5(7):549-563
61. Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol Sci 2007;28(6):286-295
62. Schreiber S, Feagan B, DHaens G, et al. Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohns disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006;4(3):325-334
63. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum 2009;60(5):1232-1241
64. Cohen P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr Opin Cell Biol 2009;21(2):317-324
65. Yanagi S, Inatome R, Takano T, Yamamura H. Syk expression and novel function in a wide variety of tissues. Biochem Biophys Res Commun 2001;288(3):495-498
66. Furumoto Y, Nunomura S, Terada T, et al. The FcepsilonRIbeta immunoreceptor tyrosine-based activation motif exerts inhibitory control on MAPK and IkappaB kinase phosphorylation and mast cell cytokine production. J Biol Chem 2004;279(47):49177-49187
67. Wong WS, Leong KP. Tyrosine kinase inhibitors: a new approach for asthma. Biochim Biophys Acta 2004;1697(1-2):53-69
68. Wong BR, Grossbard EB, Payan DG, Masuda ES. Targeting Syk as a treatment for allergic and autoimmune disorders. Expert Opin Investig Drugs 2004;13(7):743-762
69. Ulanova M, Duta F, Puttagunta L, et al. Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis. Expert Opin Ther Targets 2005;9(5):901-921
70. Ruzza P, Biondi B, Calderan A. Therapeutic prospect of Syk inhibitors. Expert Opin Ther Pat 2009;19(10):1361-1376
71. Hisamichi H, Naito R, Toyoshima A, et al. Synthetic studies on novel Syk inhibitors. Part 1: Synthesis and structure-activity relationships of pyrimidine-5-carboxamide derivatives. Bioorg Med Chem 2005;13(16):4936-4951
72. Villasenor AG, Kondru R, Ho H, et al. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes. Chem Biol Drug Des 2009;73(4):466-470
73. Pine PR, Chang B, Schoettler N, et al. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. Clin Immunol 2007;124(3):244-257
74. Podolanczuk A, Lazarus AH, Crow AR, et al. Of mice and men: an open-label pilot study for treatment of immune thrombocytopenic purpura by an inhibitor of Syk. Blood 2009;113(14):3154-3160
75. Karin M. The IkappaB kinase - a bridge between inflammation and cancer. Cell Res 2008;18(3):334-342
76. Uwe S. Anti-inflammatory interventions of NF-kappaB signaling: potential applications and risks. Biochem Pharmacol 2008;75(8):1567-1579
77. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol 2007;8(1):49-62
78. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005;5(10):749-759
79. Chariot A. The NF-kappaB-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009;19(8):404-413
80. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science 2001;293(5534):1495-1499
81. Dejardin E, Droin NM, Delhase M, et al. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity 2002;17(4):525-535
82. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 2004;3(1):17-26
83. Hideshima T, Chauhan D, Richardson P, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-16647
84. Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. J Biol Chem 2003;278(3):1450-1456
85. Luedde T, Assmus U, Wustefeld T, et al. Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest 2005;115(4):849-859
86. Podolin PL, Callahan JF, Bolognese BJ, et al. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB Kinase 2, TPCA-1 (2-[(aminocarbonyl)amino]-5-(4- fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell Proliferation. J Pharmacol Exp Ther 2005;312(1):373-381
87. Sommers CD, Thompson JM, Guzova JA, et al. Novel tight-binding inhibitory factor-kappaB kinase (IKK-2) inhibitors demonstrate target-specific anti-inflammatory activities in cellular assays and following oral and local delivery in an in vivo model of airway inflammation. J Pharmacol Exp Ther 2009;330(2):377-388
88. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 2004;23(48):7990-8000
89. Groves T, Smiley P, Cooke MP, et al. Fyn can partially substitute for Lck in T lymphocyte development. Immunity 1996;5(5):417-428
90. Molina TJ, Kishihara K, Siderovski DP, et al. Profound block in thymocyte development in mice lacking p56lck. Nature 1992;357(6374):161-164
91. Straus DB, Weiss A. Genetic evidence for the involvement of the lck tyrosine kinase in signal transduction through the T cell antigen receptor. Cell 1992;70(4):585-593
92. Goldman FD, Ballas ZK, Schutte B, et al. Defective expression of p56lck in an infant with severe combined immunodeficiency. J Clin Invest 1998;102(2):421-429
93. Hubert P, Bergeron F, Ferreira V, et al. Defective p56Lck activity in T cells from an adult patient with idiopathic CD4+ lymphocytopenia. Int Immunol 2000;12(4):449-457
94. Snow RJ, Cardozo MG, Morwick TM, et al. Discovery of 2-phenylamino- imidazo[4,5-h] isoquinolin-9-ones: a new class of inhibitors of lck kinase. J Med Chem 2002;45(16):3394-3405
95. Chen P, Iwanowicz EJ, Norris D, et al. Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: improvement of cell potency. Bioorg Med Chem Lett 2002;12(21):3153-3156
96. Das J, Moquin RV, Lin J, et al. Discovery of 2-amino-heteroaryl- benzothiazole-6- anilides as potent p56(lck) inhibitors. Bioorg Med Chem Lett 2003;13(15):2587-2590
97. Goldberg DR, Butz T, Cardozo MG, et al. Optimization of 2-phenylaminoimidazo [4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase. J Med Chem 2003;46(8):1337-1349
98. Chen P, Doweyko AM, Norris D, et al. Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2- chloro-6-methylphenyl)-2-(3-methyl-1- piperazinyl)imidazo- [1,5-a]pyrido[3,2-e] pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity. J Med Chem 2004;47(18):4517-4529
99. Maier JA, Brugel TA, Sabat M, et al. Development of N-4,6-pyrimidine- Nalkyl- N-phenyl ureas as orally active inhibitors of lymphocyte specific tyrosine kinase. Bioorg Med Chem Lett 2006;16(14):3646-3650
100. Martin MW, Newcomb J, Nunes JJ, et al. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J Med Chem 2006;49(16):4981-4991
101. Burchat AF, Calderwood DJ, Friedman MM, et al. Pyrazolo[3,4-d] pyrimidines containing an extended 3-substituent as potent inhibitors of Lck - a selectivity insight. Bioorg Med Chem Lett 2002;12(12):1687-1690
102. Burchat A, Borhani DW, Calderwood DJ, et al. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg Med Chem Lett 2006;16(1):118-122
103. Ramos-Casals M, Fonollosa-Pla V, Brito-Zeron P, Siso-Almirall A. Targeted therapy for systemic sclerosis: how close are we? Nat Rev Rheumatol 2010;6(5):269-278
104. Fedorov O, Muller S, Knapp S. The (un)targeted cancer kinome. Nat Chem Biol 2010;6(3):166-169
105. Katz P, Whalen G, Kehrl JH. Differential expression of a novel protein kinase in human B lymphocytes. Preferential localization in the germinal center. J Biol Chem 1994;269(24):16802-16809
106. Zhong J, Gavrilescu LC, Molnar A, et al. GCK is essential to systemic inflammation and pattern recognition receptor signaling to JNK and p38. Proc Natl Acad Sci USA 2009;106(11):4372-4377
107. Bouzakri K, Ribaux P, Halban PA. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. J Biol Chem 2009;284(41):27892-27898
108. Bouzakri K, Zierath JR. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 2007;282(11):7783-7789
109. Wright JH, Wang X, Manning G, et al. The STE20 kinase HGK is broadly expressed in human tumor cells and can modulate cellular transformation, invasion, and adhesion. Mol Cell Biol 2003;23(6):2068-2082
110. Ohno H, Uemura Y, Murooka H, et al. The orally-active and selective c-Fms tyrosine kinase inhibitor Ki20227 inhibits disease progression in a collagen-induced arthritis mouse model. Eur J Immunol 2008;38(1):283-291
111. Marshall D, Cameron J, Lightwood D, Lawson AD. Blockade of colony stimulating factor-1 (CSF-I) leads to inhibition of DSS-induced colitis. Inflamm Bowel Dis 2007;13(2):219-224
112. Inaba T, Gotoda T, Harada K, et al. Induction of sustained expression of proto-oncogene c-fms by platelet-derived growth factor, epidermal growth factor, and basic fibroblast growth factor, and its suppression by interferon-gamma and macrophage colony-stimulating factor in human aortic medial smooth muscle cells. J Clin Invest 1995;95(3):1133-1139
113. Patel S, Player MR. Colony-stimulating factor-1 receptor inhibitors for the treatment of cancer and inflammatory disease. Curr Top Med Chem 2009;9(7):599-610
114. Wang X, Mader MM, Toth JE, et al. Complete inhibition of anisomycin and UV radiation but not cytokine induced JNK and p38 activation by an aryl-substituted dihydropyrrolopyrazole quinoline and mixed lineage kinase 7 small interfering RNA. J Biol Chem 2005;280(19):19298-19305
115. Jandhyala DM, Ahluwalia A, Obrig T, Thorpe CM. ZAK: a MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell Microbiol 2008;10(7):1468-1477
116. Manley PW, Drueckes P, Fendrich G, et al. Extended kinase profile and properties of the protein kinase inhibitor nilotinib. Biochim Biophys Acta 1804(3):445-453
117. Rix U, Remsing Rix LL, Terker AS, et al. A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. Leukemia 2010;24(1):44-50
118. Al-Qahtani A, Xu Z, Zan H, et al. A role for DRAK2 in the germinal center reaction and the antibody response. Autoimmunity 2008;41(5):341-352
119. Ramos SJ, Hernandez JB, Gatzka M, Walsh CM. Enhanced T cell apoptosis within Drak2-deficient mice promotes resistance to autoimmunity. J Immunol 2008;181(11):7606-7616
120. McGargill MA, Choy C, Wen BG, Hedrick SM. Drak2 regulates the survival of activated T cells and is required for organ-specific autoimmune disease. J Immunol 2008;181(11):7593-7605
121. Hegedus Z, Czibula A, Kiss-Toth E. Tribbles: a family of kinase-like proteins with potent signalling regulatory function. Cell Signal 2007;19(2):238-250
122. Yamamoto M, Uematsu S, Okamoto T, et al. Enhanced TLR-mediated NF-IL6 dependent gene expression by Trib1 deficiency. J Exp Med 2007;204(9):2233-2239
123. Sung HY, Francis SE, Crossman DC, Kiss-Toth E. Regulation of expression and signalling modulator function of mammalian tribbles is cell-type specific. Immunol Lett 2006;104(1-2):171-177
124. Deng J, James CH, Patel L, et al. Human tribbles homologue 2 is expressed in unstable regions of carotid plaques and regulates macrophage IL-10 in vitro. Clin Sci (Lond) 2009;116(3):241-248
125. Liu J, Wu X, Franklin JL, et al. Mammalian Tribbles homolog 3 impairs insulin action in skeletal muscle: role in glucose-induced insulin resistance. Am J Physiol Endocrinol Metab 2009;298(3):E565-76
126. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 2005;23(3):329-336
127. Dambach DM. Potential adverse effects associated with inhibition of p38alpha/beta MAP kinases. Curr Top Med Chem 2005;5(10):929-939
128. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60(2):335-344
129. Schindler JF, Monahan JB, Smith WG. p38 pathway kinases as anti-inflammatory drug targets. J Dent Res 2007;86(9):800-811
130. Liang J, Choi J, Clardy J. Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 A resolution. Acta Crystallogr D Biol Crystallogr 1999;55(Pt 4):736-744